Identification of an Unexpected Impurity in a New Improved Synthesis of Lesinurad

Article abstract of DOI:10.1021/acs.oprd.8b00316

An unexpected phenomenon concerning an otherwise common impurity of lesinurad has been observed in the context of synthetic process development. A new industrial process was designed as a chlorine-free process, but the critical chlorinated impurity 10 was surprisingly detected in the isolated product. Because of the structural similarity of the impurity and the product, no efficient separation of 10 by conventional methods (e.g., crystallization) was discovered. The formation of the impurity was explained by a chlorine impurity in a commercial brominating agent. This communication also describes control of the critical impurity.

Full text of DOI:10.1021/acs.oprd.8b00316

Subscriber access provided by the Henry Madden Library | California State University, Fresno
Communication
Identification of an Unexpected Impurity in
a New Improved Synthesis of Lesinurad.
Aleš Halama, Jan Stach, Stanislav Rádl, and Kristýna Benediktová
Org. Process Res. Dev., Just Accepted Manuscript • DOI: 10.1021/acs.oprd.8b00316 • Publication Date (Web): 29 Nov 2018
Downloaded from http://pubs.acs.org on November 30, 2018
Just Accepted
“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted
online prior to technical editing, formatting for publication and author proofing. The American Chemical
Society provides “Just Accepted” as a service to the research community to expedite the dissemination
of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in
full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully
peer reviewed, but should not be considered the official version of record. They are citable by the
Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore,
the “Just Accepted” Web site may not include all articles that will be published in the journal. After
a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web
site and published as an ASAP article. Note that technical editing may introduce minor changes
to the manuscript text and/or graphics which could affect content, and all legal disclaimers and
ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or
consequences arising from the use of information contained in these “Just Accepted” manuscripts.
is published by the American Chemical Society. 1155 Sixteenth Street N.W.,
Washington, DC 20036
Published by American Chemical Society. Copyright © American Chemical Society.
However, no copyright claim is made to original U.S. Government works, or works
produced by employees of any Commonwealth realm Crown government in the
course of their duties.

Page 1 of 12
Organic Process Research & Development
1
2
3
4
5
6
Identification of an Unexpected Impurity in a New Improved
Synthesis of Lesinurad.
7
8
Aleš Halama,* Jan Stach, Stanislav Rádl, Kristýna Benediktová
9
Zentiva k.s., Department of Chemical Synthesis, U kabelovny 130, Prague 102 01, Czech Republic
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
ACS Paragon Plus Environment

Organic Process Research & Development
Page 2 of 12
1
2
3
4
5
6
TOC
7
8
9
N
N
N
N
N N
"chlorine-free" process
O
OH
OH
SH
Br
S
Cl
S
N
N
N
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
O
O
N
Br
(0.1-1 %)
chlorinated impurity
O
lesinurad
commercial reagent
ACS Paragon Plus Environment

Page 3 of 12
Organic Process Research & Development
1
2
3
4
5
6
7
8
9
ABSTRACT: An unexpected phenomenon concerning otherwise common impurity of lesinurad 1 has
been observed in the context of a synthetic process development. New industrial process was designed
as a chlorine-free process but critical chlorinated impurity 10 was surprisingly detected in the isolated
product. Due to structural similarity of the impurity and the product, no efficient separation of the impurity
10 by conventional methods, e.g. a crystallization, was discovered. Formation of the impurity was
explained by chlorine impurity in commercial brominating agent. The communication also describes
control of the critical impurity.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
KEYWORDS: Lesinurad, bromination, brominating agent, protection of carboxylic acids, synthetic
process development
INTRODUCTION
Lesinurad 1 (Fig. 1) is an active pharmaceutical substance which inhibits the activity of uric acid
transporter 1 (URAT1) and organic anion transporter 4 (OAT4).1 URAT1 is a major transporter enzyme
responsible for reuptake of uric acid from the renal tubules; inhibition of URAT1 function thereby
increases excretion of uric acid. Lesinurad (marketed by AstraZeneca as Zurampic) is used in an oral
therapy for the treatment of hyperuricemia associated with gout. Lesinurad should not be used as a
monotherapy but in combination with a xanthine oxidase inhibitor (Fig. 1), e.g. allopurinol (Zyloprim).1
For that reason it was also approved for the treatment of gout as a fixed-dose combination with
allopurinol (trade name Duzallo).2
N N
OH
O
N
Br
S
N
O
N
NH
N
H
1
allopurinol
lesinurad
Fig. 1 Molecular structures of lesinurad 1 and allopurinol.
Chemical syntheses of lesinurad usually consist of three steps starting from two commercially
available 1,2,4-triazoles (2 and 3). Processes may proceed by two different pathways (Scheme 1) but
always do include sulfur alkylation, bromination and final conversion, most often a hydrolysis, leading to
the target molecule.3-7 Derivatives of bromo or chloro acetic acids were generally used as alkylating
agents in the sulfur alkylation, namely relevant esters, amides or nitrile, the most often methyl ester. The
crucial transformation in both pathways is the introduction of bromine into the structure of the advanced
intermediates.
In the first case, the amino group is replaced by bromine by a modification of the Sandmeyer reaction
using a complex mixture of BnEt3NBr, CHBr3, NaNO2, and Cl2CHCOOH.3, Conversion of 5-amino-1,2,4-
triazole 4 to methyl ester 6, according to this procedure, is carried out with large excess of NaNO2 in the
presence of dichloroacetic acid and benzyltriethylamonium chloride, where toxic and potentially
carcinogenic bromoform is used as the source of bromine. In the latter cases, the hydrogen atom is
replaced in compound 5 by the action of suitable brominating agents, e.g. NBS or bromine-pyridine
complex.4,6 The final step according to Scheme 1 is hydrolysis of appropriate lesinurad derivative;
advantageously of its methyl ester 6 but other alternatives, such as the corresponding nitrile or amide
were also mentioned.3-5
ACS Paragon Plus Environment

Organic Process Research & Development
Page 4 of 12
1
2
3
4
5
Scheme1. Reported synthetic routes of lesinurad 13-6
6
7
PATHWAY A
8
9
OMe
N
N
N N
X
OMe
O
H2N
SH
H2N
S
4
N
N
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
bromination
method A
O
N
N
S-alkylation
N
N
OH
OMe
Br
S
1
N
Br
S
6
N
K2CO3, DMF
X = Cl or Br
O
O
hydrolysis
2
bromination
method B
PATHWAY B
OMe
X
N
N
N N
OMe
O
H
SH
H
S
5
N
N
O
S-alkylation
bromination method A: BnEt3NBr, CHBr3, NaNO2, Cl2CHCOOH
bromination method B: NBS in THF or Br2, pyridine in acetonitrile
hydrolysis: LiOH or NaOH then acidifying by HCl, HBr or AcOH
K2CO3, DMF
X = Cl or Br
3
Knowledge of impurities and methods of reducing their content in the desired product has an important
relevance for each manufacturing process of a pharmaceutical substance. According to assessment
report for Zurampic made by EMA, lesinurad may commonly contain four known significant organic
impurities (Fig. 2), namely amino impurity 7, hydroxy impurity 8, desbromo impurity 9, and chloro
impurity 10.8 The same impurities are also described in two recent patent applications.4,7 The content of
these impurities in the final substance depends on synthetic method and can be reduced in the final
steps of the synthetic process, when e.g. isolated crude sodium salt of lesinurad is purified by
crystallization from water and free acid 1 is isolated after acidification by acetic, hydrobromic or
hydrochloric acids. Unfortunately the purification procedure leading to lesinurad 1 in pharmaceutical
quality is rather complex process which usually requires repeated operations, see Scheme 2.4,9
N N
N N
OH
OH
HO
S
H2N
S
7
N
N
O
O
8
N N
N
N N
N
OH
OH
H
S
9
Cl
S
O
O
10
Fig. 2 Molecular structures of known organic impurities of lesinurad 1.4,7,8
ACS Paragon Plus Environment

Page 5 of 12
Organic Process Research & Development
1
2
3
4
Scheme 2. Reported process of purification of lesinurad4,9
5
6
7
8
9
N N
N
N N
N
N N
N
N N
N
ONa
OMe
OH
OH
Br
S
Br
S
Br
S
Br
S
O
O
O
O
(a)
(c)
(b)
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
crude methyl ester 6
crude lesinurad 1
sodium lesinurad 11
and its crystallization
pure lesinurad 1
(a) 1. NaOH / H2O 2. AcOH, (b) NaOH / H2O (c) 1. HBr 2. EtOAc / n-heptane
In spite of the fact that many synthetic processes have been described already, there is still a need
for new and improved processes for the production of lesinurad characterized by easier work up, more
cost-effective syntheses, utilisation of less toxic reagents, higher overall yield and, last but not least, by
obtaining the product with a high level of chemical purity. The bromination is generally considered as
the crucial synthetic step in lesinurad syntheses because it affects both yield and product quality. In
order to develop a practical commercial process for lesinurad production, we have recently designed,
developed and patented a new synthetic procedure, complying with all of the above mentioned
requirements.7
RESULTS AND DISCUSSION
Introduction to the chlorine-free synthetic process. Our primary aim has been a new industrial
process for lesinurad 1 characterized by easy implementation, advantageous management and control
of impurities, in particular of the chlorinated impurity 10. Initial finding, based on our preliminary effort in
direct bromination of acid 12, proved low stability of the carboxylic group, including sulfur-containing
side chain, and confirmed the necessity of its protection in the course of bromination.7 For that reason,
a modified chlorine-free process has recently been proposed and developed, see Scheme 3.7 The key
feature of the new process is in situ protection of the carboxylic acid group in 12 prior to the bromination,
e.g. by the trimethylsilyl group (TMS).7 Other key features in the process involve utilisation of readily
available brominating agents and new lesinurad salts for efficient isolation, e.g. 1a and 1b. In spite of
the fact, that the process was designed as a chlorine-free, chlorinated impurity 10 was surprisingly still
detected in the product. Results related to this issue as well as the solution of the problem are presented
in this communication.
TMS group replaces hydrogen in the carboxylic functional group to form an intermediate which is
already resistant to undesirable reactions. Because of moisture sensitivity, cleavage of TMS derivatives
can be achieved simply by hydrolysis under mild conditions. For that reason lesinurad, or better its
crystalline salt, can be conveniently isolated in the course of the reaction mixture work up without the
need for a further manufacturing step. And what is essential, many well-known TMS-agents have been
described as efficient for the protection of carboxylic acids and some of them are readily commercially
available, e.g. N,O-bis(trimethylsilyl)acetamide (BSA), N,O-bis(trimethylsilyl)carbamate (BSC),
N,N’-bis(trimethylsilyl)urea (BSU) and 3-trimethylsilyl-2-oxazolidinone (TMSO), see Fig. 3.10 The
specific advantage of these TMS-reagents is, in particular, the fact that they do not require addition of a
base or a catalyst for successful trimethylsilylation.
ACS Paragon Plus Environment

Organic Process Research & Development
Page 6 of 12
1
2
3
4
Scheme 3. Improved process for lesinurad synthesis7
5
6
7
8
N
N
N N
N
N
OH
OSi(CH3)3
OSi(CH3)3
S
S
Br
S
N
N
N
O
O
O
BSA / THF
or
DBDMH
NBS
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
not isolated
14 not isolated
12
13
N
N
N N
N
N
OH
OH
O
R1
R1
H2N
Br
S
1
Br
S
Br
S
1
N
N
N
HN
O
R2
O
O
H2O
R2
HBr
1a R1 = H, R2 = isoPr
1b R1 = R2 = Et
isolation and purification
not isolated
BSA is one of the most potent and commonly used silylating reagents.10 It is characterized by high
silylation potential, neutral silylating conditions, simple handling (BSA is a stable liquid) and relatively
low price. BSA is commercially easily available, it does not require addition of a supplementary base for
successful protection and its by-products (N-TMS-acetamide and acetamide) are generally acceptable.
Due to these facts we have chosen BSA as all-round advantageous TMS-agent for protecting
intermediate 12 before bromination.
H
OSi(CH3)3
NSi(CH3)3
BSA
(H3C)3SiN
OSi(CH3)3
O
BSC
Si(CH3)3
N
H
H
(H3C)3SiN
NSi(CH3)3
O
O
O
TMSO
BSU
Fig.3 TMS-agents suitable for protecting of carboxylic acids.10
In line with our consideration we found out that an in situ TMS-protected intermediate 13 can be
selectively brominated using readily available brominating agents. We have considered and screened
several bromination agents (Fig. 4), e.g. N-bromosuccinimide (NBS), 1,3-dibromo-5,5-
dimethylhydantoin (DBDMH), dibromoisocyanuric acid (DBICA) and pyridinium tribromide (PTB).11 With
regard to commercial availability and easy handling we selected two cheapest (NBS and DBDMH) as
suitable agents to optimize the bromination method.
O
O
O
Br
O
HN
N
N
Br
N
Br
N
O
N
Br
N
Br3
H
O
Br
O
DBICA
PTB
NBS
DBDMH
Fig. 4 Suitable brominating agents.11
ACS Paragon Plus Environment

Page 7 of 12
Organic Process Research & Development
1
2
3
4
5
6
7
8
Other typical feature of the process is isolation and purification of lesinurad via well crystallizing
ammonium salts with suitable bases such as isopropyl amine or diethyl amine. Isopropyl amine salt 1a
is preferred with respect to the achieved yields and efficient purification effect. The salt 1a was found
efficient for removing most impurities formed during the synthesis with the exception of the chlorinated
impurity 10. Isolated crude crystalline salt 1a usually had HPLC purity over 99.4%.
9
Scheme 4. New “chlorine-free” process
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
N N
N
N N
N
N N
N
OH
OH
BrCH2COOH
BSA / THF
1. S-alkylation by
2. protection by
SH
Br
S
Cl
S
O
O
3. bromination by
or
DBDMH
NBS
4. isolation via salt, e.g. with isopropylamine
5. liberation of lesinurad by HBr
(0.1-1 %)
chlorinated impurity 10
3
lesinurad 1
New synthetic process has been designed as chlorine-free process and it, in brief description, consists
of five consecutive steps as follows: alkylation of commercially available 1,2,4-triazole 3 by bromoacetic
acid, protection of acid 12, bromination, lesinurad salt isolation and final liberation of lesinurad 1, see
Scheme 4. The protection of carboxylic acid 12 by TMS group is performed by action of BSA (2 eq) in
THF, the following bromination is carried out by addition of NBS (2 eq) or DBDMH (1 eq). Mixing
brominating agents directly with THF at ambient temperature should be avoided for the sake of safety
due to limited stability and possible exothermic decomposition.12 From that reason it is necessary to add
a brominating agent as the last component to the solution acid 12, BSA and THF. A brominating agent
can be added either in a solid state optionally in the form of a cooled solution of brominating agent in
THF. The solution of brominating agent in THF should be constantly kept below 10 °C.
The reaction mixture is then stirred at approx. 55 °C to achieve complete conversion of the carboxylic
acid 12 (at least 99.9%). The conversion of the starting material can be advantageously monitored by
HPLC analyses of the reaction mixture during bromination, see Fig. 5. Approx. 3h are needed for full
conversion under the above described reaction conditions. THF used as reaction medium is then
changed by 4-methyl-2-pentanone; resulting organic solution is washed by water, solution of sodium
thiosulfate and saturated solution of sodium bromide. Isopropyl amine (alternatively diethyl amine) is
added to the washed and dried solution of lesinurad; crude lesinurad isopropyl amine salt is then isolated
and purified by re-crystallization. Finally free acid is liberated after addition of hydrobromic acid and
crude lesinurad 1 is purified by re-crystallization to obtain final product in pharmaceutical quality.
Fig. 5 HPLC analyses of the reaction mixture in the course of bromination of acid 12 to lesinurad 1 at
55 °C and at different times (a) 0min, (b) 20min, (c) 1h, (d) 2h, (e) 3h.
Unexpected occurrence of the chlorinated impurity in chlorine-free process. New synthetic
process, as was mentioned above, has been designed as a chlorine-free process. That means that all
chlorinated agents used in former processes (such as hydrochloric acid, chloroacetic acid, dichloroacetic
ACS Paragon Plus Environment

Organic Process Research & Development
Page 8 of 12
1
2
3
4
5
6
7
8
9
acid, benzyltriethylamonium chloride and sodium chloride) as well as chlorinated solvents to prevent
any chlorine source for production chlorine impurity 10 were strictly avoided. In spite of this precaution,
we just recognized the serious issue in the case of chlorinated impurity 10 which has been occasionally
observed in the product in amounts significantly over limit (0.15%), sometimes even over 1%. We were
able to purify crude lesinurad in the form of its salt 1a from many minor impurities by means of
crystallization. Unfortunately these crystallizations do not have any positive effect regarding the content
of chlorinated impurity 10. The same issue was observed in case of isolation of lesinurad 1 and its
purification by crystallization.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
The impurity 10 was specifically observed when commercial NBS was used as a brominating agent.
On the other hand, when commercial DBDMH was used, chlorinated impurity in the product was either
not detectable or not exceeding the limit, see Scheme 5. It is apparent that impurity 10 comes from
brominating agent which is contaminated by its chloro analogue (e.g. by NCS in case of NBS). It is
known that bromine may be contaminated by chlorine depending on the method of its industrial
production. The manufacture of bromine involves direct reaction of chlorine with brine rich in bromine
ions.13 This contamination can be transmitted to brominating agents. Unfortunately, the level of chloro
analogues’ content in brominating agents is not commonly reported in commercially available sources.
Undefined contamination then poses significant risk to both development and production of
pharmaceutical substances prepared from commercially available brominating agents.
Scheme 5. Halogenation reaction of carboxylic acid 12 under different conditions
1 free of imp. 10
1 contamined by imp. 10
BSA/THF
NBS (recrystallized)
or DBDMH commercial)
BSA/THF
NBS (commercial)
N N
N
N N
N N
N
N N
N
OH
OH
OH
OH
BSA/THF
NCS / NBS
(equimolar)
BSA/THF
NCS / AIBN
Cl
S
S
N
Cl
S
Br
S
1
O
O
O
O
10
12
10
BSA/THF
NCS
isolated as
diethylamine salt
major
minor
(approx. 2.5:1)
no chlorination
Several halogenation experiments of carboxylic acid 12 under different conditions have been carried
out. Practically no chlorination product was detected when halogenation by NCS was done under
identical conditions used for bromination by NBS. If a radical initiator, e.g. AIBN, was added,
chlorination took place but a little bit slowly in comparison with bromination. Standard of impurity 10 in
the form of its salt with diethyl amine was prepared using this procedure. If equimolar mixture of
chlorinating (NCS) and brominating (NBS) agents was used, chlorination takes place preferentially,
approx. 2.5 times faster than bromination (Fig. 6). If commercial NBS was used, product contaminated
by impurity 10 was isolated (usually 0.1-1%). On the other hand, if commercial DBDMH or re-crystallized
NBS was used, obtained product was free of impurity 10. It has been experimentally shown that
chlorination is more than twice preferred in competition with bromination what is resulting in much higher
content of chlorinated impurity in desired product than it would correspond to the original contamination
of the commercial brominating agent, see Scheme 5. Experimental results show that brominating agents
easily generate the bromine radical without the need for a special initiation. On the other hand, the
chlorine radical reacts faster in the sense of halogenation, but a special initiation is needed to generate
it in the reaction mixture. I is obvious that the conventional reagents (e.g. AIBN) as well as the bromine
radicals generated in situ in the reaction mixture can play role as chlorine radical activator.
ACS Paragon Plus Environment

Page 9 of 12
Organic Process Research & Development
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Fig. 6 HPLC analyses of the reaction mixture in the course of halogenation of acid 12 to lesinurad 1
and chlorinated impurity 10 in THF at 55 °C by mixture NBS (1 eq) and NCS (1 eq) at different times
(a) 0min, (b) 20min, (c) 1h, (d) 2h, (e) 3h.
CONCLUSION
Presented new process is designed as a chlorine-free process based on unconventional bromination of
carboxylic acid 12 protected in situ with TMS-group. Serious issue concerned with a surprising
occurrence of chlorinated impurity 10 has been successfully solved. This impurity results from utilization
of commercially available brominating agent, especially NBS, which has been slightly contaminated by
its chlorine analogue. Lesinurad 1 has finally been obtained in high chemical purity (HPLC>99.8%)
which conforms to the regulatory requirements. New process has been optimized for the future scale up
and full production. Potential contamination of brominating agents with their chlorine analogues is not
easily detectable and for that reason may have a general adverse impact on the development of
bromine-containing pharmaceutical products.
EXPERIMENTAL SECTION
Analytical Methods. 1H and 13C NMR spectra were measured with a Bruker Avance 500 spectrometer
with the measuring frequencies of 500.131 MHz and 125.762 MHz respectively. The spectra were
measured in DMSO-d6. 1H chemical shifts were related to TMS (δ = 0.00 ppm) and 13C chemical shifts
to DMSO-d6 (δ = 39.5 ppm). Melting points were measured on a Kofler block with the sample heating
speed of 10 °C (to 70 °C) and 4 °C (over 70 °C) per minute and are uncorrected. HPLC chromatograms
were measured with the EliteLachrom device made by the Hitachi Company. Stationary phase: RP-18e
was used for the analyses; column temperature was 20 °C. Mobile phase: Acetonitrile (A) and a 0.02 M
aqueous solution of KH2PO4 (B) adjusted to pH 2.7 with aqueous H3PO4 (50%) were used. A gradient
mode with the flow rate of the mobile phase was 1.0 mL/min. Composition on the start was 40% of A
and 60% of B, this composition was held for 1 min., than changed to 80% of A and 20% of B over 14
minutes, this composition was held for 15 min., then changed to 40% of A and 60% of B over 3 min. and
this composition was held to the end (overall time 36 min.). Detection at the wavelength of 230 nm was
used. Methanol was used as the solvent for preparation of samples; 10-20 μL of the solution was used
for the injection. The HPLC method was used for checking the compositions of the reaction mixtures as
well as purity of isolated compounds.
2-[[4-(4-Cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl]thio]acetic acid (12). Triazole 3 (54.0
g, 0.202 mol) and ethanol (300 ml) were mixed at room temperature (25 °C). Then a solution of sodium
bicarbonate (22 g) and water (300 ml) was added. The mixture was intensively stirred and heated to 45
°C. The neutralized solution of bromoacetic acid in water was gradually and carefully added to the
mixture of starting material, water and sodium bicarbonate. This partially neutralized solution has
formerly been prepared by gradual addition of sodium bicarbonate (27.0 g) to a stirred solution of
bromoacetic acid (32.0 g, 0.232 mol) in water (200 ml) at room temperature. The reaction mixture was
intensively stirred at 55 °C for a one hour. The resulting solution was acidified by addition of acetic acid
ACS Paragon Plus Environment

Organic Process Research & Development
Page 10 of 12
1
2
3
4
5
6
7
8
9
(200 ml) at 45-50 °C and stirred at room temperature overnight. Resulting precipitated solid was
collected by filtration. The cake was washed with water (3x50 ml) and ethyl acetate (2x50 ml). Isolated
solid was dried in the open air at room temperature for several hours at first and then in a vacuum dryer
1
at 60 °C for 4 hours to give product as a white powder. Yield 60.4 g, 91.9%, HPLC 99.94%. H NMR
(DMSO-Dd6), δ(ppm): 0.84 (m, 2H); 1.15 (m, 2H); 2.54 (m, 1H) ; 4.01 (s, 2H) ; 7.21 (d, J = 8.5 Hz, 1H);
7.41 (d, J = 7.63, 1H); 7.55 (d, J = 7.63 Hz, 1H); 7.64 (t, J = 7.3 Hz, 1H); 7.74 (t, J = 7.3 Hz, 1H); 8.57
(d, J = 8.5 Hz, 1H); 8.89 (s, 1H) ; 12.94 (bs, 1H). 13C NMR (DMSO-d6), δ(ppm): 7.0; 7.3; 34.4; 122.1;
122.6; 125.0; 125.5; 127.2; 127.4; 127.8; 128.8; 133.4; 142.3; 146.5; 150.5; 169.3.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
2-[[5-Bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl]thio]acetic acid isopropyl
amine salt (1a). Acid 12 (65.0 g, 0.200 mol) and tetrahydrofuran (300 ml) were mixed at room
temperature (20-25 °C), and then N,O-bis(trimethylsilyl)acetamide (74 ml, 0.303 mol, 1.5 eq) was added.
The mixture was stirred to obtain a clear solution and then brominating agent (2 eq. of re-crystallized
NBS, 72.0 g) and THF (30 ml) were added. The reddish-brown reaction mixture was stirred at 55 °C for
3 hours and then gradually cooled to room temperature. 4-Methyl-2-pentanone (350 ml) was added to
the reaction mixture and diluted reaction mixture was concentrated by vacuum distillation (55-60°C / 200
to 100 mbar). THF was distilled off during this operation (approx. 350 ml). Remaining dark brown-red
solution was washed with water (250 ml), 10 % solution of sodium thiosulfate pentahydrate
(Na2S2O3.5H2O) in water (250 ml), water again (250 ml), saturated solution of sodium bromide in water
(250 ml, ca 237 g NaBr) and dried over sodium sulfate (25 g). Drying agent was filtered off and washed
with acetone (250 ml). Isopropyl amine (17 ml, 0.198 mol, 1 eq) dissolved in acetone (100 ml) was added
to the filtered solution at room temperature (20-25 °C). The mixture was stirred at 22-23 °C for 16 hours.
Precipitated product was isolated by vacuum filtration. The cake was washed with warm acetone (twice
40 ml, approx. 45 °C), 2-butanol (once 40 ml, approx. 50 °C) and dried in the open air at room
temperature for several hours to give the product as a creamy to pale ochre powder. Yield 74.0 g, 79.9%,
HPLC 96.31% (no impurity10 observed). Re-crystallization of 1a. The crude salt 1a (73.0 g) was
dissolved in methanol (200 ml) at 55 °C and then 2-butanol (200 ml) was added. The mixture was
concentrated by vacuum distillation (60-70°C / 400 to 300 mbar). Methanol was distilled off during this
operation (approx. 200 ml). The suspension was stirred at 65-70 °C for 15 min. Resulting thick
suspension was filtered while hot by means of vacuum. The cake was washed with hot 2-butanol (50
ml, approx. 50 °C). Isolated crystalline solid was dried in the open air at room temperature overnight at
first and then in a vacuum dryer at 60 °C for 2 hours to give product as an off white powder. Yield 47.7
g, 65.3%, HPLC 99.40% (no impurity10 observed). 1H NMR (DMSO-d6), δ(ppm): 0.88 (m, 2H); 1.12 (d,
J = 6.4 Hz, 2H); 1.14 (m, 2H); 2.54 (m, 1H); 3.20 (sept, 1H); 3.68 (m, 2H); 7.12 (d, J = 8.5 Hz, 1H); 7.43
(d, J = 7.6 Hz, 1H); 7.64 (t, J = 7.3 Hz, 1H); 7.73 (t, J = 7.3 Hz, 1H); 7.89 (bs, NH3+); 8.57 (d, J = 8.5 Hz,
1H). 13C NMR (DMSO-d6), δ(ppm): 7.1; 7.3; 13.0; 20.6; 42.7; 121.8; 122.8; 125.1; 127.1; 127.2; 128.0;
128.8; 130.3; 133.5; 142.8; 155.9; 167.9. Note (1) Alternatively, 3-dibromo-5,5-dimethylhydantoin
DBDMH (1eq, 57.5 g) was used instead of NBS to perform the bromination. Other reaction conditions
remain the same. The yield was 49.3 g (67.6%, HPLC 99.39%). Note (2) When commercial NBS was
used, a product 1a contaminated with 0.5-1.0% of chlorinated impurity 10 was obtained.
Procedure for re-crystallization of commercial NBS. A commercial NBS (100 g, e.g. Sigma-Aldrich,
product number B81255) and de-ionized water (400 ml) were mixed at room temperature (20-25 °C),
and then gradually heated to 90-95 °C. The result was a clear red solution and bromine vapours over
the solution. The mixture was gradually cooled to room temperature for at least 2 hours. Resulting
suspension was furthermore stirred at 5 °C overnight. Precipitated solid was filtered off and washed with
water (3x50 ml). Wet product was then dried in the open air at room temperature for several hours at
first and then in a vacuum over silica at room temperature overnight. Isolated product was stored at dark
and dry place at 5-10 °C. Yield 69.2 g, 69.2%.
2-[[5-Bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl]thio]acetic acid (1). Isopropyl
amine salt 1a (34.5 g, 0.074 mol) was dissolved in water (140 ml) at 60-65°C. Acetone (170 ml) was
gradually added to this still hot solution. 2M Hydrobromic acid (43 ml) was added drop-wise to the still
hot solution in water-acetone mixture. The solution was stirred under gradual cooling to 20-25 °C for 4
hours. Precipitated solid was collected by suction. The cake was washed by 50 ml of a mixture of
acetone and water (1:1). Isolated solid was dried in the open air at room temperature overnight at first
ACS Paragon Plus Environment

Page 11 of 12
Organic Process Research & Development
1
2
3
4
5
6
7
8
9
and then in a vacuum dryer at 55 °C for 2 hours to give product as an off white powder. Yield 24.4 g,
81.1%, HPLC 99.80% (no impurity10 observed). Re-crystallization of 1. Crude lesinurad acid (24.0 g)
was dissolved in acetone (150 ml) at 55 °C. Heptane (150 ml) was added to this solution and the mixture
stirred at 55 °C for 5 minutes and then gradually cooled to 20-25 °C for 2 hours. Precipitated solid was
collected by suction. The cake was washed by heptane (25 ml). The isolated crystalline solid was dried
in the open air at room temperature overnight and then in a vacuum dryer at 55 °C for 6 hours to give
product as an off white powder. Yield 19.2 g, 63.8% (for synthetic step incl. re-crystallization), HPLC
99.89% (no imp.10 observed). 1H NMR (DMSO-d6), δ(ppm): 0.87 (m, 2H); 1.15 (m, 2H); 2.56 (m, 1H);
4.00 (m, 2H); 7.16 (d, J = 8.5 Hz, 1H); 7.44 (d, J = 7.3, 1H); 7.64 (d, J = 7.3 Hz, 1H); 7.66 (t, J = 7.6 Hz,
1H); 7.74 (t, J = 7.6 Hz, 1H); 8.58 (d, J = 8.5 Hz, 1H); 12.99 (s, COOH). 13C NMR (DMSO-d6), δ(ppm):
7.3; 7.4; 12.9; 34.1; 121.8; 122.7; 125.2; 126.6; 126.8; 127.3; 128.1; 128.6; 131.4; 133.5; 143.2; 153.5;
169.0.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
2-[[5-Chloro-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl]thio]acetic
acid
diethyl
amine salt 10. DEA (standard of impurity 10). The Acid 12 (16.3 g, 0.050 mol) and THF (120 ml) were
mixed at room temperature (20-25 °C), and then BSA (17 ml, 0.070 mol, 1.4 eq) was added. The mixture
was stirred to obtain clear solution, then AIBN (1.7 g) and chlorinating agent (12.5 g NCS, 0.094 mol,
1.9 eq) were added. The reaction mixture was stirred at 55 °C for 4 hours (incomplete conversion);
second portion of NCS (7.5 g, 0.056 mol, 1.1 eq) was added and stirred at 55 °C overnight. The mixture
was concentrated by vacuum distillation and the rest was dissolved in dichloromethane (250 ml). The
solution was washed by water (50 ml), 2M HCl (50 ml), water again (50 ml) and brine (50 ml). Organic
solution was dried over sodium sulphate and filtered. The solution was concentrated by vacuum
distillation. The rest was dissolved in acetone and diethyl amine is added (5 ml). The mixture was stirred
at room temperature overnight. The precipitated solid was filtered off, washed with hot acetone (35 ml,
50 °C), then with acetone (15 ml) at room temperature and with diethyl ether (twice 20 ml). Isolated solid
1
was dried at open air overnight. Yield 5.5 g, 25.3%, HPLC 95.4%, m.p. 125-128°C. H NMR (DMSO-
D6), δ(ppm): 0.88 (m, 2H); 1.10 (t, J = 7.3 Hz, 6H); 1.15 (m, 2H); 2.55 (m, 1H); 2.81 (q, J = 7.3, 1H); 3.73
(m, 2H); 7.19 (d, J = 8.5 Hz, 1H); 7.45 (d, J = 7.6, 1H); 7.66 (m, 2H); 7.75 (t, J = 7.3 Hz, 1H); 7.73 (t, J
+
= 7.32 Hz, 1H); 8.59 (d, J = 8.50 Hz, 1H); 9.15 (bs, Et2NH2 ). 13C NMR (DMSO-D6), δ(ppm): 7.2; 7.4;
11.1; 13.0; 41.0; 121.7; 122.7; 125.2; 126.8; 126.2; 127.2; 128.1; 128.7; 133.5; 141.6; 143.0; 155.2;
168.7.
AUTHOR INFORMATION
Corresponding Author
e-mail: ales.halama@centrum.cz
ACKNOWLEDGMENT
We have no words to express our deepest appreciation to the management of Zentiva k.s. for kind
support of this work especially for excellent leadership of our department. Close cooperation with
colleagues from the Development department is greatly appreciated. Especially we thank Dr. Josef
Zezula for helpful grammar revision.
REFERENCES
(1) (a) Hoy, S. M. Lesinurad: First Global Approval. Drugs 2016, 76 (4), 509-516. (b) Bobulescu I. A.;
Moe O. W. Renal Transport of Uric Acid: Evolving Concepts and Uncertainties. Adv. Chronic Kidney
Dis. 2012, 19, 358-371.
(2) The Medical Letter on Drugs and Therapeutics: Lesinurad/Allopurinol (Duzallo) for Gout-
Associated Hyperuricemia J. Am. Med. Assoc. 2018 319 (2), 188-189.
ACS Paragon Plus Environment

Organic Process Research & Development
Page 12 of 12
1
2
3
4
5
6
(3) (a) Quart, B. D.; Girardet, J. L.; Gunic, E.; Yeh, L. T. Preparation of azole carboxylates as
modulators of blood uric acid levels. WO2009070740 A2, 2009. (b) Meng Q. ; Zhao T.; Kang D. ;
Huang B.; Zhan P.; Liu X. The development of an effective synthetic route of lesinurad (RDEA594).
Chem. Central J. 2017, 11:86.
7
8
9
(4) Gunic, E.; Galvin, G. Manufacture of 2-[5-bromo-4-(cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-
ylthio]acetic acid and related compounds. WO2014008295 A1, 2014.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
(5) Chen, W.; Luo, J.; Liu, L.; Fan, Y. A process for the preparation of thiotriazole derivatives.
WO2014198241 A1, 2014.
(6) Wang, P.; Li, P.; Gu, X. Method for preparing medicine Lesinurad for treating gout and lesinurad
intermediate. WO2015054960 A1, 2015.
(7) (a) Stach, J.; Radl, S.; Zvatora, P.; Pisa, O.; Benediktova, K.; Halama, A. Process for preparing 2-
(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid. EP3281941 A1, 2018.
(b) Zvatora, P.; Dammer, O.; Krejcik, L.; Schongut, M.; Stach, J.; Halama, A.; Kutzendoferova, P.;
Benediktova, K.; Man, S.; Tkadlecova, M. Solid forms of lesinurad amine salts EP3372592 A1, 2018.
(8) For more information about EMA assessment report for Zurampic, see: http://www.ema.europa.eu/
docs/en_GB/document_library/EPAR_Public_assessment_report/human/003932/WC500203069.pdf.
(9) Galvin, G.; Treiber, L. R.; Zamansky, I.; Girardet, J. L. Polymorphic forms of 2-(5-bromo-4-(4-
cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof. WO2012092395
A2, 2012.
(10) (a) Klebe, J. F.; Finkbeiner, H.; White D. M. Silylations with Bis(trimethylsilyl)acetamide, a Highly
Reactive Silyl Donor. J. Am. Chem. Soc., 1966, 88 (14), 3390–3395. (b) De Koning, J. J.; Kooreman,
H. J.; Tan H. S.; Verweij J. One-step, high yield conversion of penicillin sulfoxides to
deacetoxycephalosporins. J. Org. Chem., 1975, 40 (9), 1346–1347. (c) Berry, P. D.; Brown, A. C.;
Hanson, J. C.; Kaura, A. C.; Milner, P. H.; Moores, C. J.; Quick, J. K.; Saunders, R. N.; Southgate, R.;
Whittall N. A convenient large scale synthesis of 7α-formamido cephalosporins. Tetrahedron Lett.
1991, 32 (23), 2683-2686. (d) L. Birkhofer, L.; Sommer, P. Siliciumorganische verbindungen: LXI. N-
trimethylsilyl-carbamidsäure-trimethylsilylester; ein neues silylierungsmittel. J. Organomet.
Chem.1975, 99 (1), C1-C4. (e) Verboom, W.; Visser, G. W.; Reinhoudt, D. N. N,N′-Bis[trimethylsilyl]-
urea: A Useful Silylating Agent for Alcohols and Carboxylic Acids. Synthesis 1981 (10), 807-809. (f)
Palomo, C. A Convenient Synthesis of Trimethylsilyl Carboxylates using N-Trimethylsilyl-2-
oxazolidinone in the Absence of Catalysts. Synthesis 1981 (10), 809-811.
(11) (a) Reeves, W. P.; King, R. M. A Convenient Method for Bromination of Aromatic Amines Synth.
Commun. 1993, 23 (6), 855-855. (b) Baraldi, P. G.; Bazzanini, R.; Manfredini, S.; Simoni, D.; Robins,
M. J. Facile access to 2′-O-acyl prodrugs of 1- (β-D-arabinofuranosyl)-5(E)-(2-bromovinyl)uracil
(BVAraU) via regioselective esterase-catalyzed hydrolysis of 2′ 3′, 5′-triesters Tetrahedron Lett. 1993,
34 (19), 3177-3180. (c) Cabaj, J. E.; Kairys, D.; Benson, T. R. Development of a Commercial Process
to Produce Oxandrolone Org. Process Res. Dev. 2007, 11 (3), 378-388.
(12) Shimizu, S.; Imamura, Y.; Ueki, T. Incompatibilities between N-Bromosuccinimide and Solvents
Org. Process Res. Dev., 2014, 18 (2), 354–358.
(13) Yalçin, H.; Koç, T.; Pamuk, V. Hydrogen and bromine production from concentrated sea-water Int.
J. Hydrogen Energy 1997, 22, (10–11), 967-970.
ACS Paragon Plus Environment